Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Launched by UNIVERSITY OF FLORIDA · Sep 27, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new group counseling program designed to help people cope with the negative feelings and stigma associated with certain health conditions, such as obesity, skin diseases, cancer, HIV, diabetes, and chronic pain. The goal is to see if this support can reduce the internalized stigma many patients experience, which can impact their mental health and overall quality of life. Participants in this study will attend virtual group meetings for a total of six months, sharing their experiences and supporting each other.
To be eligible for the trial, you need to be at least 18 years old and have one of the specified health conditions, along with feelings of stigma related to your health. Participants will need access to a computer or device with video capabilities and the ability to understand and speak English, as the sessions will be conducted in English. Even if you don't have a device or internet, arrangements can be made to help you participate. This study is a chance for individuals to connect with others facing similar challenges and gain tools to improve their well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older
- * At least one of the following stigmatized health conditions:
- • Obesity (or high body weight that negatively affects health)
- • Skin disease (including but not limited to psoriasis, eczema, or vitiligo)
- • Cancer (including but not limited to lung, breast, cervical, colorectal, gynecologic, prostate, or head and neck; including individuals in remission)
- • HIV
- • Type 1 or type 2 diabetes
- • Chronic pain
- • Reported internalization of health-related stigma, as determined by a pre-specified cutoff score on internalized stigma measure and confirmed by interview
- • Participants must have availability to attend weekly virtual group meetings for 12 weeks, followed by every-other-week and monthly meetings through 26 weeks, in the evening on a specified weekday. Participants must be willing to actively participate and share information about themselves in the group meetings.
- • Participants must be able to read, comprehend, and speak English in order to participate in group sessions and complete study questionnaires.
- • Participation requires an electronic device (computer, tablet, or phone) with video capabilities and internet, wi-fi, or cellular data in order to attend group sessions and complete study questionnaires. Individuals who do not have such devices or internet access will still be eligible to participate. In such cases, screening procedures will be conducted by phone, and randomized participants will be provided with web cameras or internet-enabled devices (and/or provided with pre-paid cellular data) to facilitate participation.
- Exclusion Criteria:
- • Current or recent (e.g., past 3 months) receipt of psychotherapy or a psychosocial or peer support intervention (exceptions may be made if therapy or support is not focused on health conditions and is unlikely to affect internalized health-related stigma; e.g., family or marriage counseling, religious study groups, etc.)
- • Psychiatric hospitalization in the past 6 months
- • Recent (e.g., past 3 months, approximately) change in medications taken for psychiatric reasons
- • Current, active suicidal thoughts or suicide attempt within the past year
- • Current or past thought disorder or psychosis, or unmanaged bipolar disorder
- • Current alcohol/substance use disorder that requires immediate treatment
- • Health-related stigma due primarily to mental illness or substance use, or due to health conditions not specified in inclusion criteria.
- • No reported internalization of health-related stigma and/or score below pre-specified cutoff on internalized stigma measure
- • Unwilling or unable to complete study procedures
- • Participants with severe progression of disease (e.g., end-of-life) or who are undergoing acute, intensive treatment (such as chemotherapy or radiation therapy) will not be eligible to participate due to expected impacts on HRQOL and greater needs for psychological support than the intervention is intended to provide. Such participants may be eligible after completion of acute treatment or if severe symptoms remit and/or prognosis improves.
About University Of Florida
The University of Florida, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials. With a focus on enhancing patient outcomes and exploring new therapeutic avenues, the university leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct rigorous research across a variety of medical fields. Committed to ethical standards and patient safety, the University of Florida fosters collaboration among researchers, healthcare professionals, and community stakeholders to translate scientific discoveries into impactful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gainesville, Florida, United States
Patients applied
Trial Officials
Rebecca Pearl, PhD
Principal Investigator
University of Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials